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Abstract
AIM: To evaluate serum levels of N-terminal pro-brain 
natriuretic peptide (NTproBNP) and tumor necrosis 
factor α (TNF-α) in a large series of patients with 
hepatitis C associated with mixed cryoglobulinemia 
(MC+HCV).
METHODS: Serum NTproBNP and TNF-α levels were 
assayed in 50 patients with MC+HCV, and in 50 sex- 
and age-matched controls. 
RESULTS:  Cryoglobul inemic pat ients showed 
significantly higher mean NTproBNP and TNF-α levels 
than controls (P  < 0.001; Mann-Whitney U  test). By 
defining high NTproBNP level as a value higher than 
125 pg/mL (the single cut-off point for outpatients 
under 75 years of age), 30% of MC+HCV and 6% 
of controls had high NTproBNP (χ2, P  < 0.01). With 
a cut-off point of 300 pg/mL (used to rule out heart 
failure (HF) in patients under 75 years of age), 8% 
of MC+HCV and 0 controls had high NTproBNP (χ2, P  
< 0.04). With a cut-off point of 900 pg/mL (used for 
ruling in HF in patients aged 50-75 years; such as the 
patients of our study), 6% of MC+HCV and 0 controls 
had high NTproBNP (χ2, P  = 0.08).
CONCLUSION: The study demonstrates high levels of 
circulating NTproBNP and TNF-α in MC+HCV patients. 
The increase of NTproBNP may indicate the presence 
of a subclinical cardiac dysfunction.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
The most common clinical features of  hepatitis C 
associated with mixed cryoglobulinemia (MC+HCV) 
are correlated with vasculitis in the various organs and 
sometimes with increased viscosity of  the plasma[1,2]. 
Signs and symptoms include purpura, ulcers of  the 
extremities, arthralgia, proteinuria, hepatic damage, 
abdominal pain, mental confusion, oligo-anuria, 
hemorrhagic diathesis, and sometimes congestive heart 
failure (HF)[1-4]. Furthermore, HF has been described 
as heralding the clinical onset of  essential mixed 
cryoglobulinemia (MC)[5]. Moreover, many MC+HCV 
patients experience symptoms such as fatigue, dyspnea 
and reduced physical activity. However, in many patients, 
these symptoms are not proportional to the liver 
involvement and resemble symptoms of  HF.
Several studies have shown that plasma levels of  
brain natriuretic peptide (BNP) and N-terminal proBNP 
(NTproBNP) are reliable diagnostic and prognostic 
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markers for cardiac disease[6,7] that correlate with 
symptoms of  HF and the severity of  systolic and diastolic 
dysfunction[8]. Some authors have recently stated that 
NTproBNP appears superior to BNP for the evaluation 
of  suspected acute HF in patients with preserved 
left ventricular ejection fraction[9,10]. In the study by 
O’Donoghue et al[9], NTproBNP seems to correlate with 
HF severity better than BNP and is more sensitive. 
Cytokines play an important role in chronic HF, 
and it has been shown that TNF-α and NTproBNP are 
independent predictors of  long-term risk of  death[11,12] 
for HF. Circulating TNF-α has been recently shown to 
be high in patients with MC[13].
However, to our knowledge, until now no study has 
evaluated circulating NTproBNP together with TNF-α 
levels, as possible markers of  HF, in MC+HCV patients 
affected by cryoglobulinemic vasculitis.
The aim of  this study was to evaluate serum levels 
of  NTproBNP in a series of  MC+HCV patients, and to 
correlate this parameter with the clinical features of  the 
disease, and with the circulating levels of  TNF-α.
MATERIALS AND METHODS
Patients
Fifty MC+HCV patients (37 females and 13 males; 
mean age 57 ± 9 years; mean disease duration 10 ± 11 
years), consecutively referred to our Rheumatology Unit, 
were recruited for the study between 2001 and 2006. The 
diagnosis of  MC+HCV was based on the presence of  
serum mixed (IgG-IgM) cryoglobulins and the classical 
clinical triad, purpura, weakness, arthralgias, and on the 
exclusion of  other well-known systemic disorders, such 
as immuno-rheumatic and neoplastic diseases[1,2,14-16].
The study included only patients with MC+HCV, 
without liver cirrhosis or hepatocellular carcinoma 
(assessed by histology, laboratory evidence of  liver failure 
and/or ultrasound-proven portal hypertension)[17,18]. 
None of  the patients had evident signs of  HF, organic 
renal disease (patients with serum creatinine > 1.2 mg/dL 
and/or proteinuria > 0.5 g/24 h were excluded), thyroid 
disease, diabetes, cancer or any other major diseases. All 
patients had normal cardiac physical examinations and 
normal blood pressure. 
Thirty eight out of  55 (76%) MC+HCV patients 
underwent liver biopsy for diagnostic purposes; liver 
histology activity index (grade) or stage of  liver fibrosis 
were evaluated according to Ishak et al[19]. The mean 
activity index (grade) in MC+HCV patients was 5.0 ± 
1.2, and the mean stage was 2.0 ± 0.9. Main demographic 
and clinico-serological features of  MC+HCV patients 
are reported in Table 1. 
Among the patients, 17 had been previously treated 
with interferon-alpha (IFN-α) for an average of  7 mo 
(range, 1-13 mo), at a mean dosage of  10.4 MU/wk; 
the time elapsed from the last course of  IFN-α 
treatment ranged from 6 to 69 mo (mean 40 ± 22 mo). 
No statistically significant differences were observed in 
the main demographic and clinico-serological features 
of  MC+HCV patients treated or untreated with IFN-α.
At the time of  study, 35 MC+HCV patients were 
taking low doses of  corticosteroids, 8 had previously 
been on corticosteroids and 7 had never been treated 
with corticosteroids. No MC+HCV patient had had 
plasma exchange treatment in the last year before the 
study. In both patients and controls, a careful medical 
history was collected, in particular with regard to family 
history of  thyroid disease, smoking habits, and drugs. 
The presence of  Raynaud’s phenomenon, Sjogren’s 
syndrome, skin ulcers, peripheral neuropathy, and 
renal and liver involvement in MC+HCV patients was 
evaluated as previously described[16]. Routine blood 
chemistry was carried out by standard methods. 
Controls 
Each of  the 50 MC+HCV patients eligible for the study 
was matched, by sex and age, one-to-one with a control 
group of  healthy subjects of  the general population 
from the same geographic area (North-West Tuscany). 
This control group was extracted from a larger sample 
of  1640 subjects taking part in a population-based 
survey of  thyroid disorders; only HCV-negative subjects, 
without clinical and laboratory evidence of  thyroid and 
liver disorders or autoimmune diseases and not treated 
with immunomodulators were included.
None of  the controls had signs of  HF, organic renal 
disease, thyroid disease, diabetes, cancer or any other 
major diseases. All patients had normal cardiac physical 
examination results and normal blood pressure.
Extraction of  the control group from the original 
population was performed by finding the closest age 
match (± 2 years) to each case within either gender. 
When more than one age-match was available per case, 
the choice was made at random. 
The study protocol was approved by the local Ethics 
Committee. All subjects gave their informed consent to 
enter the study.
Age (yr) 57 ± 9
Male/female 13/37









Aminotransferase elevation and/or histologic activity1 71%
Cryocrit (%)    4.2 ± 8.9
CH50 (normal: 160-220 U) 111 ± 36 
C3 (normal: 60-130 mg/dL)   81 ± 36 
C4 (normal: 20-55 mg/dL)   14 ± 18
Autoantibodies2 25%
Table 1  Demographic and clinico-serological features of 50 
MC+HCV patients
1Increase of the liver enzyme (alanine aminotransferase) and/or liver his-
tological alterations. 2Presence of anti-nuclear and/or anti-mitochondrial 
and/or anti-smooth muscle and/or anti-extractable nuclear antigen auto-
antibodies. MC+HCV: Hepatitis C associated with mixed cryoglobulinemia.
www.wjgnet.com
Immunological studies 
Cryocrit was measured as the percentage of  packed 
cryoglobulins after cold centrifugation of  the serum; 
cryoglobulin composition was determined by the 
incorporation in cryoprecipitates of  monoclonal or 
polyclonal IgM-rheumatoid factor (i.e. MC type Ⅱ or MC 
type Ⅲ); hemolytic complement C3-C4 fractions were 
measured as previously described[16], anti-nuclear, anti-
smooth muscle, and anti-mitochondrial autoantibodies 
were detected by current techniques[16]. Sera with a titre 
> 1:40 were considered positive. Anti-extractable nuclear 
antigen antibodies, including anti-Scl70, -Sm, -RNP, 
-SSA/SSB, -PCNA, -SL and -Jo1 specificities, were 
detected by counter-immunoelectrophoresis according 
to the methods described by Bunn et al[20].
Virological studies
Antibodies against HCV (anti-HCV) and HCV-RNA 
were determined in serum clotted and centrifuged at 37℃ 
and stored at -70℃ .  Anti-HCV and HCV-RNA 
levels [assayed by polymerase chain reaction (PCR) 
technique] in the serum were investigated as previously 
described[21,22]. 
Cytokines, chemokines and analytical assays
Blood samples for analysis of  plasma NTproBNP were 
collected, centrifuged and plasma was stored at -80℃ 
until analysis. Plasma concentrations of  NTproBNP 
were measured by a sandwich immunoassay on an 
Elecsys 2010 (Roche Diagnostics, Mannheim, Germany).
Serum TNF-α concentrations were measured using 
commercially available kits (R&D Systems, Minneapolis, 
MN). The mean minimum detectable dose was 0.12 pg/mL 
for TNF-α; the intra- and inter-assay coefficients of  
variation were 5.8% and 10.2%. Samples were assayed in 
duplicate. Quality control pools of  low, normal, or high 
concentration for all parameters were included in each 
assay. Alanine aminotransferase (ALT) was assayed by 
conventional methods[18].
Statistical analysis
Values are given as mean ± SD for normally distributed 
variables, or as median ± IQR for not normally 
distributed variables (NTproBNP, TNF-α). Group values 
were compared by univariate ANOVA, for normally 
distributed variables; or by Kruskal-Wallis (≥ 3 groups) 
or Mann-Whitney U (2 groups) tests. Proportions were 
compared by the chi-square test. Post-hoc comparisons 
on normally distributed variables were carried out using 
the Bonferroni-Dunn test. Univariate analysis was 
performed by simple regression. A multivariate logistic 
regression analysis considering age, gender, ALT, and 
presence or absence of  active vasculitis as independent 
variables and presence or absence of  high levels of  
NTproBNP or TNF-α as dependent variables was 
performed in MC+HCV patients.
RESULTS
Plasma NTproBNP concentrations were significantly 
(P < 0 .001 ;  Mann-Whi tney  U  t e s t )  h igher  in 
MC+HCV patients  (mean 123 ± 112 pg/mL; median 
36 pg/mL, range 8-1547 pg/mL) than in controls (mean 
11 ± 12 pg/mL; median 3.1 pg/mL range 2-145 pg/mL) 
(Figure 1).
By defining high NTproBNP level as a value higher 
than 125 pg/mL (the single cut-off  point for outpatients 
under 75 years of  age[23]) 15/35 MC+HCV and 3/47 
controls had high NTproBNP (χ2, P < 0.002).
With a cut-off  point of  300 pg/mL (used to rule out 
HF in patients under 75 years of  age[23]) 4/46 MC+HCV 
and 0/50 controls had high NTproBNP (χ2, P < 0.041).
With a cut-off  point of  900 pg/mL (used for ruling 
in HF in patients with age 50-75; such as the patients 
of  our study[23]) 3/47 MC+HCV and 0/50 controls had 
high NTproBNP (χ2, P = 0.08). 
In order to better define the role of  increased 
serum NTproBNP in MC+HCV, mean levels of  this 
chemokine were separately evaluated (by Mann Whitney 
U test) among MC+HCV patient subgroups defined 
according to main demographic and clinical features (age 
> 55 years; gender; disease duration > 10 years; presence 
or absence of  purpura, active vasculitis, weakness, 
arthralgias, arthritis, Raynaud’s phenomenon, Sjogren’s 
syndrome, peripheral neuropathy, aminotransferase 
elevation and/or histologic activity in the liver), but 
no significance was found. No significant correlations 
were obser ved between NTproBNP levels and 
serological findings of  MC+HCV (levels of  cryocrit and 
complement, presence/absence of  autoantibodies) or 
previous/ongoing treatments.
Serum TNF-α was detectable in 85% of  controls and 
in all MC+HCV patients; mean levels were significantly 
(P < 0.01; Mann Whitney U test) higher in MC+HCV 
patients (mean 26 ± 65 pg/mL; median 8.3 pg/mL, 
range 1.3-269 pg/mL) than in controls (mean 1.6 ± 1.1 
pg/mL; median 1.2 pg/mL, range 0.6-3.4 pg/mL). No 
correlation was found between serum TNF-α and any 
of  the following; ALT level, liver histology activity index, 
stage of  liver fibrosis, the presence of  active vasculitis, or 
the other demographic, serological and clinical features 
of  MC.
MC+HCV patients had, obviously, raised ALT 
enzymes (P < 0.0001), in comparison with controls. 
a




















Figure 1  Plasma NTproBNP circulating levels (were significantly higher in 
MC+HCV patients than in controls; Mann Whitney U test). aP < 0.05 vs control.
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No association was observed between NTproBNP or 
TNF-α levels and ALT levels in the MC+HCV patients. 
DISCUSSION
Our study demonstrates the presence of  significantly 
high serum levels of  NTproBNP in patients with 
MC+HCV compared to healthy controls. Furthermore, 
our study confirms significantly high serum levels of  
TNF-α in patients with MC+HCV compared to healthy 
controls. 
Some authors have recently stated that NTproBNP 
appears superior to BNP for the evaluation of  suspected 
acute HF in patients with preserved left ventricular 
ejection fraction[9,10]. Furthermore[9], NTproBNP seems 
to correlate with HF severity better than BNP and 
appears more sensitive. The International Collaborative 
for NTproBNP Study (ICON) helped in defining 
appropriate cut-off  points for NTproBNP in the 
emergency department[23]: 300 pg/mL should be used 
to rule out HF, while 450 pg/mL, 900 pg/mL, or 
1800 pg/mL, depending on age (< 50, 50-75, or > 
75 years; respectively), should be applied for ruling 
in HF. The age stratifications do offer significant 
positive predictive value. For outpatient evaluation 
the manufacturer suggested a single cut-off  point of  
125 pg/mL for patients under 75 years of  age and 450 pg/mL 
for patients above 75 years of  age[23].
The levels of  NTproBNP found in MC+HCV are 
included in a gray zone (125-900 pg/mL) that is not 
necessarily associated with HF, however in 3/50 (6%) of  
MC+HCV patients the NTproBNP levels were higher 
than 900 pg/mL, which is the cut-off  value for ruling in 
HF for patients of  age 50-75 years, such as the patients 
of  our study. Since NTproBNP level seems to correlate 
with HF severity, the values in the gray zone may be 
suggestive of  a subclinical cardiac impairment. The 
exclusion of  patients with renal failure from the study 
suggests that the NTproBNP increase is not related to 
any kidney involvement in the MC+HCV patients.
In a previous work, Matsumori et al[24] showed there 
was a significantly higher NTproBNP level in HCV 
patients and observed that the presence of  anti-HCV 
antibodies in sera was more prevalent in patients with 
myocarditis and HF than in the general population. 
Future studies comparing NTproBNP levels between 
HCV and MC+HCV patients will be needed to evaluate 
the specific influence of  the cryoglobulinemic vasculitis.
The findings of  the present study may have 
important implications for patients with MC+HCV. 
Most patients complain about fatigue, dyspnea and 
reduced physical capacity. The pathogenesis of  these 
symptoms is not well understood and sometimes 
attributed to the liver injury. However, it seems possible 
that these patients experience cardiac impairment 
which could at least contribute to these symptoms. 
Furthermore, among signs and symptoms of  MC+HCV, 
sometimes congestive HF may be found, which in some 
cases has been described as heralding the clinical onset 
of  essential MC[3-5].
Testing of  NTproBNP level may serve as a screening 
marker for cardiac insufficiency in the differential 
diagnosis of  fatigue and dyspnea and may aid the 
decision for further diagnostic testing of  cardiac 
function as has been described for other groups 
of  patients[25-28]. Besides diagnostic consequences, 
evaluation of  NTproBNP may have therapeutic 
consequences for patients with MC+HCV. In patients 
with known congestive HF, elevated plasma BNP 
concentrations could be reduced by treatment with ACE 
inhibitors[29] or angiotensin Ⅱ receptor antagonists[30] 
as well as treatment with diuretics and vasodilators[31]. 
As a consequence, plasma NTproBNP concentration 
may guide the intensity of  pharmacotherapy as some 
interventional studies have suggested[32,33].
Cytokines play an important role in chronic HF, 
and it has been shown that TNF-α and NTproBNP are 
independent predictors of  long-term risk of  death[11,12] 
for patients with HF.
Our study confirms a high serum TNF-α level in 
HCV+ve patients, as previously demonstrated in other 
studies of  HCV+ve patients[34-36]. The increase of  
TNF-α in MC+HCV patients is unlikely to be due to 
a more aggressive liver disease; in fact, no correlation 
was found between TNF-α levels and ALT levels, or 
with degree of  liver inflammation in our study[13]. Other 
studies have shown an increased production of  TNF-α 
by lymphocytes in MC+HCV patients[37,38], suggesting 
that the increase of  TNF-α may be due to activation of  
lymphoid cells.
The fact that TNF-α and NTproBNP are independent 
predictors of  long-term risk[11] is in agreement with the 
results of  our study; in fact, no relationship has been 
observed between TNF-α and NTproBNP. 
It has been shown that combining measurements 
of  pro-inflammatory cytokine TNF-α and NTproBNP 
seems a promising tool in the prognostic assessment of  
HF patients[12]. However, even if  we have shown that 
NTproBNP and TNF-α are both high in the circulation 
of  MC+HCV patients, we cannot exclude that different 
pathogenetic pathways may be differentially implicated 
in the increase of  each of  these factors.
The interest in finding reliable markers of  cardiac 
dysfunction is intensified by studies that strongly 
suggest an association between HCV chronic infection 
and atherosclerotic disease in the carotid or coronary 
artery[39-41].
In conclusion, our study shows elevated levels of  
NTproBNP in patients with MC+HCV, in association 
with TNF-α. This may indicate the presence of  cardiac 
dysfunction and explain, at least in part, some of  the 
clinical symptoms of  patients with MC+HCV. Further 
larger, possibly multicenter prospective studies quantifying 
symptoms and correlating these with echocardiographic 
parameters are needed to confirm this association.
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cryoglobulinemia (MC+HCV) are correlated with vasculitis in various organs 
and heart failure (HF) has been described as heralding the clinical onset of 
essential mixed cryoglobulinemia (MC). To our knowledge, until now no study 
has evaluated circulating NTproBNP together with TNF-α levels as possible 
markers of HF, in MC+HCV patients affected by cryoglobulinemic vasculitis.
Innovations and breakthroughs
This study demonstrates elevated serum levels of NTproBNP in patients 
with MC+HCV, in association with high TNF-α levels. This may indicate the 
presence of cardiac dysfunction and explain, at least in part, some of the 
clinical symptoms of patients with MC+HCV who have no evident signs of HF. 
Further larger, possibly multicenter prospective studies quantifying symptoms 
and correlating these with echocardiographic parameters are needed to confirm 
this association.
Applications
NTproBNP evaluation may serve as a screening marker for cardiac 
insufficiency in the differential diagnosis of fatigue and dyspnea, may aid 
the decision for further diagnostic testing of cardiac function and may have 
therapeutic and diagnostic consequences for patients with MC+HCV. In patients 
with known congestive HF, elevated plasma BNP concentrations could be 
reduced by treatment with ACE inhibitors, angiotensin Ⅱ receptor antagonists 
and treatment with diuretics and vasodilators. As a consequence, plasma 
NTproBNP concentration may guide the intensity of pharmacotherapy as some 
interventional studies have suggested.
Terminology
Plasma levels of BNP and NTproBNP are reliable diagnostic and prognostic 
markers for cardiac disease which correlate with symptoms of HF and the 
severity of systolic and diastolic dysfunction. TNF-α is a cytokine involved in 
systemic inflammation and is a member of a group of cytokines that stimulate 
the acute phase reaction. Circulating TNF-α has been recently shown to be 
high in patients with MC.
Peer review
The study by authors has evaluated the circulating levels of NTproBNP and 
TNF-α in patients with HCV-related cryoglobulinemia. They found higher 
levels of both proteins in these patients as compared with normal controls 
and conclude that they may have a potential role in cardiac dysfunction of 
cryoglobulinemic patients. Though crude, these data are interesting.
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